StreetInsider.com News Articles

Form SCHEDULE 13G IRulya Therapeutics Inc. Filed by: Foresite Capital Fund VI LP

Wed, 14 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261014/27187587.html

Form SCHEDULE 13G IRulya Therapeutics Inc. Filed by: Foresite Capital Fund VI LP

Wed, 14 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261014/27187587.html

Form SCHEDULE 13G IRulya Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Wed, 14 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27187043.html

Form SCHEDULE 13G IRulya Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Wed, 14 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27187043.html

Quince Therapeutics rebrands as IRulya Therapeutics, shifts to lung drug

Fri, 09 Oct 2026 08:01:31 -0400

Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has changed its name to IRulya Therapeutics Inc., effective October 9, 2026, refocusing the company on the clinical development of LAM-001, an investigational inhaled formulation of rapamycin targeting multiple pulmonary diseases.

The company's common stock will begin trading on the Nasdaq Capital Market under the ticker symbol "IRLA" on October 12, 2026. The name change follows the completion of Quince's merger with privately held Orphai Therapeutics and a concurrent private placement that raised approximately $115 million in gross proceeds in May 2026. The company reported a cash balance of $116 million as of June

Quince Therapeutics rebrands as IRulya Therapeutics, shifts to lung drug

Fri, 09 Oct 2026 08:01:31 -0400

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Fri, 09 Oct 2026 08:00:00 -0400

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026

Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D.

Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise

Cash balance of $116 million as of June 30, 2026 expected to fund operations through the end of 2028, supporting anticipated clinical data readouts from Phase 2 studies of LAM-001 in BOS, PH-ILD, and SAPH

SOUTH SAN

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Fri, 09 Oct 2026 08:00:00 -0400

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026

Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D.

Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise

SOUTH SAN

Form 8-K Quince Therapeutics, For: Oct 07

Fri, 09 Oct 2026 07:59:00 -0400

si-local-file:///var/storage/secattach/20261009/27169294.html

Raymond James Starts Quince Therapeutics Inc. (QNCX) at Outperform

Fri, 09 Oct 2026 06:06:47 -0400

(Updated - October 9, 2026 6:06 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Outperform rating and a price target of $72.00.

The analyst comments "We are initiating coverage of Quince Therapeutics (QNCX) at Outperform with a $72 target price. Following Quince’s acquisition of Orphai Therapeutics in May 2026, the company is now centered around LAM-001, an inhaled formulation of rapamycin for pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post-lung-transplant (BOS)."

For an analyst ratings summary and ratings history on Quince Therapeutics Inc. click here.

Raymond James Starts Quince Therapeutics Inc. (QNCX) at Outperform

Fri, 09 Oct 2026 06:06:47 -0400

(Updated - October 9, 2026 6:06 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Outperform rating and a price target of $72.00.

For an analyst ratings summary and ratings history on Quince Therapeutics Inc. click here.

Form S-8 Quince Therapeutics,

Thu, 08 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261008/27167767.html

Form 8-K Quince Therapeutics, For: Oct 06

Tue, 06 Oct 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20261006/27156208.html

Form DEFA14A Quince Therapeutics,

Fri, 02 Oct 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20261002/27138838.html

Form 8-K Quince Therapeutics, For: Sep 30

Fri, 02 Oct 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20261002/27138831.html

Quince Therapeutics (QNCX) Reiterated at Market Outperform by Citizens on LAM-001 Potential for PH-ILD

Tue, 29 Sep 2026 05:25:44 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $77.00 price target on Quince Therapeutics Inc. (NASDAQ: QNCX).

The analyst commented, "Consistent with our investment thesis, KOLs participating in the event view LAM-001 as a differentiated, potentially disease-modifying therapy that targets the vascular remodeling, fibrosis, and inflammatory pathways underlying PH-ILD and BOS. The KOLs highlighted the potential for LAM-001 to become a foundational combination therapy, complementing treprostinil in PH-ILD and serving as an add-on to standard immunosuppression in BOS. The discussion reinforced our conviction in the ongoing Phase 2b PH-ILD study, which remains the key de-risking dataset for PH-ILD, with

Rodman & Renshaw Starts Quince Therapeutics Inc. (QNCX) at Buy

Thu, 24 Sep 2026 06:32:30 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Buy rating and a price target of $70.00.

The analyst comments "We are initiating coverage of Quince Therapeutics (QNCX) with a BUY rating and $70 price target, implying ~130% upside from current levels. Quince is developing LAM-001, a once-daily dry-powder inhaled formulation of rapamycin designed to achieve direct pulmonary exposure while limiting systemic exposure associated with oral mTOR inhibition. The program addresses three high-unmet-need pulmonary indications: PH-ILD, BOS, and SAPH. Key catalysts are Ph2 BOS data in 1Q27 and Ph2b PH-ILD data in 1Q28. With

Rodman & Renshaw Starts Quince Therapeutics Inc. (QNCX) at Buy

Thu, 24 Sep 2026 06:32:30 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Buy rating and a price target of $70.00.

Citizens Upgrades Quince Therapeutics Inc. (QNCX) to Market Outperform

Tue, 22 Sep 2026 01:52:48 -0400

Citizens analyst Jonathan Wolleben upgraded Quince Therapeutics Inc. (NASDAQ: QNCX) from Market Perform to Market Outperform with a price target of $77.00.

The analyst comments: “We are upgrading our rating on Quince Therapeutics to Market Outperform and establishing a $77 risk-adjusted, DCF-derived price target following its reverse merger with Orphai Therapeutics. QNCX is developing LAM-001, a once-daily inhaled formulation of the mTOR-inhibitor rapamycin, for rare pulmonary diseases, with ongoing Phase 2 trials in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS) following lung transplantation and a third Phase 2 for sarcoidosis-associated PH starting soon.

Large, validated PH-ILD

Citizens Upgrades Quince Therapeutics Inc. (QNCX) to Market Outperform

Tue, 22 Sep 2026 01:52:48 -0400

Citizens analyst Jonathan Wolleben upgraded Quince Therapeutics Inc. (NASDAQ: QNCX) from Market Perform to Market Outperform with a price target of $77.00.

Large, validated PH-ILD

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Thu, 17 Sep 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massachusetts General Hospital), as well as BOS expert Steven Hays, MD (UCSF Health) to discuss the current treatment landscape and unmet need

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Thu, 17 Sep 2026 08:00:00 -0400

Form 8-K Quince Therapeutics, For: Sep 08

Mon, 14 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260914/27058807.html

Form 8-K Quince Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26990491.html

Form 8-K Quince Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26990491.html